推薦產品
化驗
≥98% (HPLC)
形狀
powder
儲存條件
desiccated
顏色
white to off-white
溶解度
DMSO: >10 mg/mL
儲存溫度
2-8°C
SMILES 字串
OC(=O)CC(O)(CC(O)=O)C(O)=O.CN(C)CCOc1ccc(cc1)C(=C(\CCCl)c2ccccc2)\c3ccccc3
InChI
1S/C26H28ClNO.C6H8O7/c1-28(2)19-20-29-24-15-13-23(14-16-24)26(22-11-7-4-8-12-22)25(17-18-27)21-9-5-3-6-10-21;7-3(8)1-6(13,5(11)12)2-4(9)10/h3-16H,17-20H2,1-2H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)/b26-25-;
InChI 密鑰
IWEQQRMGNVVKQW-OQKDUQJOSA-N
基因資訊
human ... ESR1(2099) , ESR2(2100)
一般說明
Toremifene is a triphenylethylene derivative. It exhibits antitumor and antiestrogen effects. Toremifene has estrogen-agonist effects on blood lipids and endometrium.
應用
Toremifene citrate salt has been used:
- in cell-based ELISA
- as a positive control to detect its antiviral activity against Ebola virus (EBOV)
- to treat MCF7 and T47D breast cancer cell lines
生化／生理作用
Toremifene citrate is an oral selective estrogen receptor modulator (SERM). It is used in advanced (metastatic) breast cancer and being evaluated for prevention of prostate cancer. Toremifene citrate is known to increase bone mineral density in prostate cancer patients undergoing androgen deprivation therapy†.
特點和優勢
This compound is featured on the Nuclear Receptors (Steroids) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
準備報告
Toremifene citrate salt is soluble in DMSO at a concentration that is greater than 10 mg/ml.
訊號詞
Danger
危險聲明
危險分類
Acute Tox. 4 Oral - Aquatic Acute 1 - Aquatic Chronic 1 - Eye Dam. 1
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
分析證明 (COA)
輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號，寫有 ‘Lot’或‘Batch’.。
客戶也查看了
Regulatory Mechanisms in Breast Cancer: Advances in Cellular and Molecular Biology of Breast Cancer (2012)
Juhyun Kim et al.
International journal of cancer, 132(6), 1475-1485 (2012-08-24)
We investigated the in vitro metabolism and estrogenic and antiestrogenic activity of toremifene (TOR), tamoxifen (TAM) and their metabolites to better understand the potential effects of cytochrome P-450 2D6 (CYP2D6) status on the activity of these drugs in women with
Matthew R Smith et al.
The Journal of urology, 189(1 Suppl), S45-S50 (2012-12-19)
Androgen deprivation therapy is associated with fracture risk in men with prostate cancer. We assessed the effects of toremifene, a selective estrogen receptor modulator, on fracture incidence in men receiving androgen deprivation therapy during a 2-year period. In this double-blind
Stefan Kudlacek et al.
Wiener medizinische Wochenschrift (1946), 162(17-18), 380-385 (2012-08-10)
Osteoporosis is defined as a continuous loss of bone mineral density accompanied by an increased fracture risk in females and males. A fall of estrogen concentrations at the menopause and the consecutive rapid bone loss are an established pathogenic mechanism
S Kallio et al.
Cancer chemotherapy and pharmacology, 17(2), 103-108 (1986-01-01)
The basic pharmacological and biochemical properties of a new antiestrogen, Fc-1157a, are described. Fc-1157a is bound specifically and with high affinity to estrogen receptors. The binding is competitive with estradiol. Fc-1157a treatment induces translocation of estrogen receptors from cytoplasm to
我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務